Oncotelic Therapeutics, Inc.

OTC:OTLC

0.04 (USD) • At close November 27, 2023
Bedrijfsnaam Oncotelic Therapeutics, Inc.
Symbool OTLC
Munteenheid USD
Prijs 0.037
Beurswaarde 14,731,883
Dividendpercentage 0%
52-weken bereik 0.01 - 0.09
Industrie Biotechnology
Sector Healthcare
CEO Dr. Vuong Trieu Ph.D.
Website https://www.oncotelic.com

An error occurred while fetching data.

Over Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of

Vergelijkbare Aandelen

Vicapsys Life Sciences, Inc. logo

Vicapsys Life Sciences, Inc.

VICP

2 USD

Medicine Man Technologies, Inc. logo

Medicine Man Technologies, Inc.

SHWZ

0.61 USD

Allied Corp. logo

Allied Corp.

ALID

0.101 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)